术后癌症复发和转移一直是癌症治疗中巨大的挑战。联合顺铂（CDDP）基化疗放疗方案是一种手术切除后某些癌症治疗的标准治疗策略。然而，CDDP的严重副作用和不令人满意的局部肿瘤浓度已经阻碍了这种联合化疗放疗的应用。因此，期望一种更好的选择能够增强CDDP基化疗放疗疗效，同时减轻与联合治疗相关的毒性反应。我们开发了一种基于纤维蛋白凝胶(Fgel)和CDDP (CDDP/Fgel)的平台，将其植入肿瘤切口并联合放疗(RT)预防术后本地肿瘤复发和远处转移。利用不完全切除原发肿瘤建立的术后皮下肿瘤小鼠模型，评估了该化疗放疗方案在术后治疗中的疗效优势。Fgel对CDDP的局部和持续释放可以增强残留肿瘤中放疗的抗肿瘤疗效，同时降低全身毒性。该方法的疗效已经在乳腺癌、异型甲状腺癌和骨肉瘤小鼠模型中得到证明。总之，我们的研究提供了一个通用平台，可用于预防术后癌症复发和转移的联合化疗放疗。版权所有©2023 Elsevier Inc.发布。

Postoperative cancer recurrence and metastasis have always been a huge challenge in cancer therapy. Concurrent cisplatin (CDDP)-based chemoradiotherapy regimen is a standard therapeutic strategy in some cancer treatment after surgical resection. However, severe side-effects and unsatisfactory local tumor concentrations of CDDP have hampered the application of this concurrent chemoradiotherapy. Therefore, a superior option that can enhance CDDP-based chemoradiotherapy efficacy with milder concurrent therapy-related toxicity is highly desirable.We developed a platform based on fibrin gel (Fgel) loaded with CDDP (CDDP/Fgel) to be implanted into the tumor bed after surgery combined with concurrent radiotherapy (RT) for the prevention of postoperative local cancer recurrence and distant metastasis. The postoperative subcutaneous tumor mouse models established by incomplete resect of primary tumors were utilized to evaluate the therapeutic advantages of this chemoradiotherapy regimen for post-surgical treatment.The local and sustained release of CDDP from Fgel could enhance the antitumor efficacy of RT in the residual tumor with lower systemic toxicity. The therapeutic benefits of this approach are demonstrated in breast cancer, anaplastic thyroid carcinoma, and osteosarcoma mouse models.In conclusion, our work offers a general platform for concurrent chemoradiotherapy to prevent post-operative cancer recurrence and metastasis.Copyright © 2023. Published by Elsevier Inc.